SCHEMBL801700

SCHEMBL801700

Cc1cc(Cl)ccc1-c1cc(-c2cccnc2)nc(Nc2n[nH]c3ccccc23)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FADS1 O60427 1/20 0.43
TRPA1 O75762 1/20 0.42
GRM4 Q14833 2/20 0.41
IDO1 P14902 1/20 0.41
LRRK2 Q5S007 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ABL1 P00519 4/20 0.39
BCR P11274 4/20 0.39
WNT1 P04628 1/20 0.39
DYRK1A Q13627 1/20 0.39
PRKCA P17252 1/20 0.39
PRKCD Q05655 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAP2K4 P45985 1/20 0.39
PDGFRB P09619 1/20 0.39
PDGFRA P16234 1/20 0.39
PAK4 O96013 2/20 0.38
KIT P10721 2/20 0.38
PDE5A O76074 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12620033 0.86 FADS1 (0.41) FADS1TRPA1GRM4IDO1LRRK2
SCHEMBL805606 0.79 GRM4 (0.43) GRM4IDO1LRRK2WNT1DYRK1A
SCHEMBL802388 0.79 GRM4 (0.43) GRM4IDO1LRRK2ABL1WNT1
SCHEMBL801694 0.79 VCP (0.43) FADS1TRPA1GRM4IDO1ALDH1A1
SCHEMBL802337 0.78 GRM4 (0.45) FADS1TRPA1GRM4LRRK2MEN1
SCHEMBL801707 0.75 USP1 (0.50) GRM4IDO1LRRK2MEN1KMT2A
SCHEMBL802377 0.73 USP1 (0.50) FADS1TRPA1GRM4IDO1LRRK2
SCHEMBL802354 0.70 FADS1 (0.49) FADS1TRPA1GRM4PAK4
SCHEMBL13055258 0.70 GRM4 (0.39) FADS1TRPA1GRM4IDO1LRRK2
SCHEMBL802027 0.69 FADS1 (0.46) FADS1TRPA1GRM4IDO1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633210-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-21 US disclosed
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, GSK3A, CDK19 FADS1 3442/4885TRPA1 4786/4885GRM4 3726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.